Discovering a new nutraceutical based on pollen extract and teupolioside: a prospective monocentric study evaluating...

Benign prostatic hyperplasia (BPH) is a common condition in men over 50, leading to lower urinary tract symptoms (LUTS). A nutraceutical containing pollen extract (Graminex® G96®) and teupolioside has shown potential in alleviating LUTS by targeting inflammation and dihydrotestosterone production. This prospective, monocentric study enrolled 60 patients with mild to moderate LUTS due to BPH.

Participants received one tablet daily for three months. Assessments included the international prostate symptom score (IPSS), quality of life (QoL), uroflowmetry, postvoid residual (PVR), and sexual function (IIEF-5, MSHQ EjD).

Fifty-three patients completed the follow-up. Significant improvements were observed in IPSS and QoL (p<0.001), with scores decreasing from 14 (11-16) at baseline to 10 (8-12) at three months and decreasing from 3 (2-3) to 2 (2-2), respectively. Uroflowmetry parameters (Qmax and PVR) improved, increasing from 12 (11-16) ml/s to 15 (11-17) ml/s and decreasing from 50 (30-55) ml to 35 (25-45) ml, respectively, without statistical significance (p>0.05). Sexual function and PSA levels remained stable, with no significant adverse effects reported.

The combination of pollen extract and teupolioside effectively alleviates LUTS in BPH patients with a favorable safety profile, particularly in avoiding sexual dysfunction.